Saturday 17 October 2026
Export RARE’s income statement to Excel — free account
Ultragenyx Pharmaceutical Inc.
RARE Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
14.54
0.63
−4.15%
Follow RARE
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 4 | 4 | 5 | 3 | 3 | 4 | 4 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 767.05 | 42.03 | 23.30 | 31.08 | 16.22 | 8.76 | 8.16 | 6.80 | 3.37 |
Altman Z-Score |
22.93 | 6.91 | 8.85 | 0.89 | 7.35 | 3.73 | (1.56) | (2.05) | (2.28) | (3.57) |
Altman Z″-Score (non-manufacturers) |
5.33 | (3.63) | 1.72 | (0.88) | 1.86 | (1.60) | (5.73) | (7.75) | (8.70) | (9.61) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(58.09) | (25.57) | (38.75) | (33.54) | (134.87) | (104.91) | (35.23) | (42.10) | (48.00) | (22.72) |
Beneish M-Score |
— | — | 14.07 | (0.53) | (1.91) | (2.38) | (3.27) | (2.08) | (2.55) | (2.68) |
P/B ratio |
5.84 | 5.46 | 3.55 | 3.70 | 7.30 | 6.18 | 9.03 | 12.86 | 14.93 | 0.00 |
Price to Tangible BV |
5.84 | 10.59 | 4.97 | 5.03 | 8.60 | 7.63 | 21.51 | 54.69 | 115.37 | 0.00 |
EV/Sales |
0.00 | 681.09 | 33.10 | 16.02 | 26.64 | 14.12 | 6.70 | 6.83 | 5.71 | 2.36 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(14.84) | (7.32) | (5.87) | (4.81) | (54.62) | (14.65) | (6.40) | (6.24) | (7.72) | (3.41) |
EV/FCF |
(13.95) | (7.24) | (5.78) | (4.49) | (41.00) | (12.05) | (4.62) | (5.68) | (7.37) | (3.26) |
Quick Ratio |
6.33 | 3.37 | 6.32 | 7.63 | 6.46 | 4.24 | 3.02 | 2.32 | 2.13 | 2.18 |
Current Ratio |
6.67 | 3.80 | 6.99 | 8.24 | 6.83 | 4.72 | 3.38 | 2.61 | 2.38 | 2.48 |
Net Debt/EBITDA |
1.59 | 0.73 | 1.30 | 1.79 | 3.79 | 2.05 | 1.19 | 1.04 | 1.19 | 1.35 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.01 | 0.09 | 0.11 | 0.19 | 0.21 | 0.24 | 0.29 | 0.37 | 0.44 |
Operating CF/Net income |
0.65 | 0.84 | 1.47 | 0.86 | 0.71 | 0.75 | 0.54 | 0.78 | 0.73 | 0.81 |
Capex/Depreciation |
(1.23) | (0.37) | (0.24) | (10.68) | (3.35) | (3.68) | (6.99) | (3.62) | (0.87) | (0.68) |
Interest Coverage |
(65.45) | (80.74) | (38.92) | (373.72) | (9.92) | (12.97) | (15.09) | (8.62) | (8.51) | (8.63) |
| (48.93%) | (70.48%) | (39.83%) | (63.79%) | (20.64%) | (43.72%) | (110.96%) | (193.34%) | (214.55%) | (657.14%) | |
| (44.70%) | (58.59%) | (32.65%) | (43.42%) | (12.89%) | (27.67%) | (46.12%) | (39.98%) | (38.01%) | (37.89%) | |
ROIC |
(167.73%) | (138.02%) | (155.57%) | 0.00% | 0.00% | (130.83%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(68.59%) | (137.08%) | (42.25%) | (50.85%) | (15.82%) | (55.61%) | (80.17%) | (81.77%) | (77.00%) | (70.90%) |
Average Days of Receivables |
0.00 | 722.73 | 90.30 | 115.59 | 31.10 | 29.53 | 40.63 | 61.72 | 79.52 | 85.69 |
Research and Development Expense of Revenue |
137,747.37% | 8,868.45% | 570.93% | 344.56% | 152.04% | 141.48% | 194.26% | 149.31% | 124.64% | 111.44% |
Selling, General and Administrative Expense of Revenue |
48,824.06% | 3,825.00% | 248.03% | 155.74% | 67.50% | 62.60% | 76.55% | 71.43% | 57.32% | 51.86% |
Intangible Assets out of Total Assets |
0.00 | 0.38 | 0.24 | 0.15 | 0.10 | 0.12 | 0.13 | 0.14 | 0.15 | 0.14 |
Share Based Compensation of Revenue |
36,322.56% | 2,603.91% | 155.56% | 79.06% | 31.63% | 29.87% | 35.88% | 31.11% | 28.21% | 22.73% |
Graham Net Nets |
0.12 | 0.08 | 0.19 | 0.15 | 0.08 | 0.05 | (0.10) | (0.14) | (0.11) | (0.29) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.33 |
Earnings Yield |
(8.86%) | (14.42%) | (8.97%) | (16.67%) | (2.26%) | (7.98%) | (22.21%) | (17.29%) | (15.07%) | (25.39%) |
Free Cash Flow Yield |
(6.18%) | (12.26%) | (13.61%) | (15.32%) | (2.09%) | (7.22%) | (16.55%) | (14.74%) | (11.40%) | (21.47%) |
Revenue per Share |
0.00 | 0.06 | 1.03 | 1.83 | 4.45 | 5.18 | 5.20 | 5.90 | 6.19 | 6.83 |
Operating CF per Share |
(4.07) | (5.98) | (5.84) | (6.10) | (2.17) | (5.00) | (5.44) | (6.46) | (4.57) | (4.73) |
Capex per Share |
(0.26) | (0.07) | (0.08) | (0.44) | (0.72) | (1.08) | (2.09) | (0.64) | (0.22) | (0.21) |
Free Cash Flow per Share |
(4.32) | (6.05) | (5.92) | (6.54) | (2.89) | (6.07) | (7.53) | (7.10) | (4.80) | (4.94) |
Cash per Share |
9.64 | 5.52 | 9.24 | 13.35 | 19.75 | 10.92 | 10.70 | 7.85 | 6.74 | 6.90 |
Shareholders Equity per Share |
11.97 | 9.03 | 12.23 | 11.56 | 18.97 | 13.61 | 5.04 | 3.75 | 2.82 | (0.81) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
11.97 | 9.03 | 12.23 | 11.56 | 18.97 | 13.61 | 5.04 | 3.75 | 2.82 | (0.81) |
Free Cash Flow |
(171.16) | (256.64) | (294.64) | (370.21) | (176.12) | (411.79) | (526.59) | (522.00) | (434.00) | (487.00) |
Working Capital |
341.44 | 198.57 | 447.64 | 747.72 | 1,105.70 | 675.24 | 622.69 | 451.75 | 473.00 | 567.00 |
Capital Expenditures |
(10.19) | (2.79) | (4.08) | (24.83) | (43.90) | (73.09) | (146.12) | (47.00) | (20.00) | (21.00) |
Net Current Asset Value |
335.04 | 162.28 | 411.72 | 369.29 | 690.12 | 256.77 | (309.05) | (483.41) | (431.00) | (661.00) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
76.60 | 1.07 | 0.08 | 0.24 | 0.16 | 0.21 | 0.40 | 0.11 | 0.04 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.48 | 0.34 | 0.84 | 0.05 | 0.18 | 0.14 | 0.08 | 0.04 | 0.09 | 0.13 |
Cash ROIC |
(20.01%) | (41.53%) | (27.57%) | (26.28%) | (7.48%) | (24.77%) | (47.86%) | (61.22%) | (50.17%) | (81.17%) |
Accounts Receivable Turnover |
0.00 | 0.99 | 5.75 | 4.55 | 9.69 | 13.64 | 10.55 | 7.63 | 5.73 | 4.81 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.11 | 0.72 | 0.48 | 1.07 | 0.94 | 1.05 | 1.90 | 3.11 |
Inventory Turnover |
— | 0.00 | 0.29 | 0.97 | 0.50 | 1.09 | 1.32 | 1.48 | 1.95 | 2.25 |
Average Days of Payables |
0.00 | 3,243,390.00 | 3,909.58 | 521.53 | 769.60 | 390.77 | 557.73 | 341.59 | 184.87 | 103.81 |
Days of Inventory on Hand |
— | 276,305.00 | 2,250.20 | 467.84 | 777.05 | 370.08 | 344.97 | 275.53 | 213.31 | 174.13 |
Average Receivables |
— | 2.64 | 8.96 | 22.79 | 27.97 | 25.76 | 34.44 | 56.92 | 97.70 | 140.00 |
Average Payables |
4.15 | 7.13 | 10.58 | 12.57 | 12.90 | 15.03 | 30.21 | 42.69 | 40.56 | 35.00 |
Average Inventory |
— | 4.00 | 3.91 | 9.31 | 12.30 | 14.64 | 21.50 | 30.37 | 39.48 | 48.50 |
Average Assets |
550.10 | 515.69 | 605.16 | 927.53 | 1,447.53 | 1,640.98 | 1,533.92 | 1,518.23 | 1,497.01 | 1,517.50 |
Average Common Equity |
502.53 | 428.71 | 496.18 | 631.34 | 904.07 | 1,038.47 | 637.53 | 313.95 | 265.21 | 87.50 |
Columns are period end dates